Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Baxter
Mallinckrodt
Colorcon

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR DIOVAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Diovan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00034840 ↗ Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed Bayer Phase 4 2001-10-01 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗ Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed GlaxoSmithKline Phase 4 2001-10-01 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗ Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed Boehringer Ingelheim Phase 4 2001-10-01 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00130156 ↗ Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed Eisai Co., Ltd. Phase 4 2005-10-01 The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.
NCT00130156 ↗ Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed Eisai Inc. Phase 4 2005-10-01 The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.
NCT00149227 ↗ Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed Kyoto Prefectural University of Medicine Phase 4 2004-01-01 The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients in Japan with hypertension in terms of the morbidity and mortality.
NCT00162955 ↗ Prevention of CHOP-induced Chronic Cardiotoxicity Completed Osaka City University Phase 4 2004-05-01 The purpose of this study is to assess the protective effect of Valsartan on chronic cardiotoxicity induced by CHOP.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diovan

Condition Name

Condition Name for Diovan
Intervention Trials
Hypertension 22
High Blood Pressure 3
Diabetes Mellitus, Type 2 2
Type 2 Diabetes Mellitus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diovan
Intervention Trials
Hypertension 25
Diabetes Mellitus 6
Essential Hypertension 6
Diabetes Mellitus, Type 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diovan

Trials by Country

Trials by Country for Diovan
Location Trials
United States 155
Korea, Republic of 10
China 8
Canada 7
Japan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diovan
Location Trials
Pennsylvania 7
Maryland 7
New York 7
Texas 6
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diovan

Clinical Trial Phase

Clinical Trial Phase for Diovan
Clinical Trial Phase Trials
Phase 4 25
Phase 3 10
Phase 2 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diovan
Clinical Trial Phase Trials
Completed 31
Unknown status 6
Terminated 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diovan

Sponsor Name

Sponsor Name for Diovan
Sponsor Trials
Novartis 7
Boryung Pharmaceutical Co., Ltd 4
Novartis Pharmaceuticals 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diovan
Sponsor Trials
Other 65
Industry 35
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.